Request Demo
Last update 14 Jun 2025
LY-3185643
Last update 14 Jun 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms LY 3185643, LY3185643 |
Target |
Action agonists |
Mechanism GCGR agonists(Glucagon receptor agonists) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with LY-3185643NCT02951780
A Randomized, 9-Way, Single-Dose, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of LY3185643 and rGlucagon in Healthy Subjects
NCT02342314
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3143753 and LY3185643 in Healthy Subjects
100 Clinical Results associated with LY-3185643
Login to view more data
100 Translational Medicine associated with LY-3185643
Login to view more data
100 Patents (Medical) associated with LY-3185643
Login to view more data
100 Deals associated with LY-3185643
Login to view more data
R&D Status
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | 23 | (10 ug LY3185643) | nadwsiierz(hwjfjhjlel) = laiobstziz fabbsdnxip (yrdmfulfoz, 49) View more | - | 30 Sep 2019 | |
(25 ug LY3185643) | nadwsiierz(hwjfjhjlel) = elljocdkow fabbsdnxip (yrdmfulfoz, 36) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free